Kadimastem Announces Publication in Frontiers in Endocrinology of a Peer-Reviewed Article
Demonstrating Advancement in the Company’s Technology to Treat Diabetes Ness Ziona, Israel, May 11th, 2021, Kadimastem (TASE: KDST), a...
top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
- Apr 26, 2021
- 3 min
Kadimastem Raises NIS 22.3 Million ($6.8 Million)
Total Potential of NIS 53.4 Million ($16 Million) with Warrants in a Private Placement Institutional investors Alpha Capital Anstalt and...
- Mar 9, 2021
- 3 min
Kadimastem Granted a Patent in Israel for the Treatment of ALS
Kadimastem Granted a Patent in Israel for the Directed Differentiation of Astrocytes from Human Pluripotent Stem Cells (AstroRx®) for use...
- Jan 31, 2021
- 5 min
Kadimastem Announces Executive Management Changes
Accomplished US Life Science and Biotech Executive Asaf Shiloni Named New CEO Company Appoints Biotech Industry Leaders Ronen Twito, CPA...
- Dec 15, 2020
- 5 min
Encouraging Results of Cohort B of its Phase 1/2a Clinical Trial of AstroRx® for ALS
No treatment-related serious adverse events nor dose-limiting toxicities were reported during the 6- month post-treatment follow up...
- Aug 3, 2020
- 7 min
Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in
AstroRx® demonstrated to be safe and well tolerated in the higher treatment dose Clinically meaningful decline in disease progression...
- Jan 2, 2020
- 7 min
Kadimastem Announces Promising Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
No treatment-related serious adverse events nor dose-limiting toxicities were reported A statistically significant decline in disease...
- Dec 23, 2019
- 4 min
Kadimastem Announces the Completion of Treatment for Cohort B
The patients in this Cohort were treated with a single dose of 250x106 cells of AstroRx® The clinical trial continues as planned. Cohort...
- Nov 19, 2019
- 4 min
Successful Preclinical results of our Cell Therapy Treatment for Insulin-Dependent Diabetes
Study results demonstrate IsletRx cells ability to balance blood sugar levels and maintain normal levels over time Unique technology...
- Nov 17, 2019
- 4 min
Kadimastem to Submit an Amendment of its ALS Phase 1/2a Clinical Trial Protocol
Following Recent Positive Interim Results The Company intends to assess the safety and efficacy of a repeated administration of the low...
- Nov 11, 2019
- 3 min
Kadimastem to Present at the 7th International Stem Cell Meeting, in Tel-Aviv
Kadimastem to Present Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS at the 7th International Stem Cell Meeting, in...
- Sep 24, 2019
- 5 min
Kadimastem Announces Promising Interim Results of Cohort A of its Phase 1/2a Clinical Trial in ALS
Disease progression was reduced in the first 3 months post-treatment period compared to the 3 months pre-treatment period, this...
- May 20, 2019
- 2 min
Kadimastem Announces Leadership Changes
NESS ZIONA, Israel, May 29, 2019 Kadimastem (TASE: KDST), a stem cell-based therapeutic company, announced recently that Yossi Ben Yosef...
- Apr 18, 2019
- 2 min
Kadimastem receives Approval from the Ministry of Health of Israel to continue its trial of AstroRX®
Ness Ziona, Israel, April 18th 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the approval from the MOH of...
- Mar 3, 2019
- 1 min
Appointment of a new CFO for Kadimastem
The Current CFO has accepted a position as the Director of the Budget Division of the Jewish Agency for Israel Ness Ziona, Israel, 3...
- Feb 24, 2019
- 2 min
Kadimastem Announces the Completion of Cell Transplantation of AstroRx® in ALS Patients for Cohort A
Ness Ziona, Israel, 24 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announced today the completion of cell...
- Feb 17, 2019
- 1 min
2019 Israel Innovation Authority Budget Approved for Kadimastem: NIS 13.6 M for ALS Project
Ness Ziona, Israel, 17 February 2019, Israeli biotechnology company Kadimastem (TASE: KDST) announces it has received approval for its...
- Nov 27, 2018
- 1 min
Kadimastem to be included in the TASE Indices
Ness Ziona, Israel, November 27, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) received an announcement from the TASE, that...
- Nov 14, 2018
- 1 min
Success for Kadimastem: 97% of Warrants (Series 4) Exercised for NIS 3.6M
Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces that, at the end of the exercise...
- Nov 12, 2018
- 2 min
Kadimastem and Defymed Awarded Grant for the Development of a Product for the Treatment of Diabetes
Ness Ziona, Israel, November 11, 2018, Israeli biotechnology company Kadimastem (TASE: KDST) announces the approval by the European Union...
bottom of page